Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) Income from Continuing Operations (2020 - 2025)

Arcutis Biotherapeutics (ARQT) has 6 years of Income from Continuing Operations data on record, last reported at 17366000.0 in Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 261.68% year-over-year to 17366000.0; the TTM value through Dec 2025 reached 16170000.0, up 88.45%, while the annual FY2025 figure was 16170000.0, 88.45% up from the prior year.
  • Income from Continuing Operations reached 17366000.0 in Q4 2025 per ARQT's latest filing, up from 7410000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 17366000.0 in Q4 2025 and bottomed at 109647000.0 in Q3 2022.
  • Average Income from Continuing Operations over 5 years is 46942750.0, with a median of 48581000.0 recorded in 2023.
  • Peak YoY movement for Income from Continuing Operations: crashed 109.27% in 2021, then skyrocketed 261.68% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 71286000.0 in 2021, then decreased by 1.03% to 72019000.0 in 2022, then grew by 7.96% to 66284000.0 in 2023, then skyrocketed by 83.8% to 10741000.0 in 2024, then surged by 261.68% to 17366000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 17366000.0 in Q4 2025, 7410000.0 in Q3 2025, and 15886000.0 in Q2 2025.